Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | TACR2 | P21452 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23459341 | 1.00 | CTSD (0.58) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL17305281 | 0.95 | CTSD (0.56) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL5963417 | 0.95 | CTSD (0.56) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL2132646 | 0.88 | CTSD (0.59) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL8270781 | 0.88 | CTSD (0.59) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL19419777 | 0.88 | CTSD (0.59) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL11470429 | 0.85 | CTSD (0.45) | CTSDPOLB | |
| SCHEMBL11476670 | 0.85 | CTSD (0.45) | CTSDPOLBDDB1CRBN | |
| SCHEMBL11472229 | 0.85 | CTSD (0.48) | CTSDPOLBDDB1CRBN | |
| SCHEMBL6974107 | 0.85 | KCNA5 (0.47) | CTSDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4069366-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021113506-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113506-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-0821674-B1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | SEARLE & CO (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6043261-A | TREATMENT OF INFLAMMATORY CONDITIONS AFFECTING THE JOINTS, FOR EXAMPLE ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CARDIOVASCULAR ISCHEMIA, DIABETES, HYPERALGESIA, CEREBRAL ISCHEMIA, THROMBOTIC STROKE, GLOBAL ISCHEMIA, NERVOUS SYSTEM DISORDERS | G. D. SEARLE & CO. (US) | 2000-03-28 | — | — | US | disclosed |
| US-6011028-A | Cyclic amidino agents useful as nitric oxide synthase inhibitors | G.D. SEARLE & CO. (US) | 2000-01-04 | — | — | US | disclosed |
| US-5883251-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0821674-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033175-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| US-4221788-A | 2-(Optionally-substituted)benzylperhydroazepines for analgesia and lowering blood pressure | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | ATM, CHEK2, CHEK1 | CTSD 4128/4885POLB 260/4885DDB1 137/4885 |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | ATM, CHEK2, CHEK1 | CTSD 4128/4885POLB 260/4885DDB1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.